Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

41 results
Display

The role of direct oral anticoagulants in venous thromboembolic disease in gynecologic cancer

Park JY

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation

Hong KS

Non-Vitamin K antagonist oral anticoagulants (NOACs) have been extensively investigated in medical conditions at high risk of venous or arterial thrombosis other than atrial fibrillation (AF), including hip or knee...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Role of Novel Oral Anticoagulants and Antiplatelet Therapy after Percutaneous Coronary Intervention: Individualizing Therapy to Optimize Outcomes

Shlofmitz , Shlofmitz , Lee MS

The number of patients undergoing percutaneous coronary intervention (PCI) who mandate additional oral anticoagulant therapy has been increasing. Dual antiplatelet therapy (DAPT) is associated with reduced ischemic events including stent...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
New Oral Anticoagulants versus Warfarin for Cerebral Venous Thrombosis: A Multi-Center, Observational Study

Wasay M, Khan M, Rajput HM, Farooq S, Memon MI, AlRukn SA, Malik A, Abd-Allah , Shoaib RF, Shahid R, Nishat S, Awan S

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Anticoagulants in Older Patients with Nonvalvular Atrial Fibrillation after Intracranial Hemorrhage

Perreault , Côté R, White-Guay B, Dorais M, Oussaïd E, Schnitzer

BACKGROUND AND PURPOSE: Patients with nonvalvular atrial fibrillation (NVAF) who survive an intracranial hemorrhage (ICH) have an increased risk of ischemic stroke and systemic embolism (IS/SE). We investigated whether starting...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation

Lee SR, Lee YS, Park JS, Cha MJ, Kim TH, Park J, Park JK, Lee JM, Kang KW, Shim J, Uhm JS, Kim J, Kim C, Kim JB, Park HW, Joung B, Choi EK

PURPOSE: Label adherence for non-vitamin K antagonist oral anticoagulants (NOACs) has not been well evaluated in Asian patients with non-valvular atrial fibrillation (AF). The present study aimed to assess label...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
2018 Korean Heart Rhythm Society Guidelines for Non-Vitamin K Antagonist Oral Anticoagulants

Park YM, Park HW, Lee JM, Park JK, Lee KH, Kim JB, Lee YS, Joung B

Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative to vitamin K antagonists (VKAs) and have emerged as the treatment of choice in Korea. However, several questions remain regarding the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The 2018 Korean Heart Rhythm Society Practical Guidelines on the use of Non-Vitamin K-Antagonist Oral Anticoagulants: Bleeding Control and Perioperative Management

Lee JH, Lim HE, Lim WH, Ahn J, Cha MJ, Park J, Lee KH, Park HC, Choi EK, Joung B

Although non-vitamin K-antagonist oral anticoagulants (NOACs) reduce major bleeding events in patients with atrial fibrillation more effectively than does warfarin, a significant bleeding risk remains. Patients exhibiting current bleeding and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
2018 KHRS Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Atrial Fibrillation: How to Initiate and Organize the Follow-up

Park JK, Kim J, Baek YS, Lee SR, Hwang YM, Kim TH, Lee DI, Lee KH, Shim J, Joung B

Non-vitamin K antagonist oral anticoagulants (NOACs) are alternatives to vitamin K antagonists to prevent stroke in patients with non-valvular atrial fibrillation (AF) and have emerged as the preferred choice. The...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants

Kim SA, Yhim HY, Bang SM

Cancer-associated venous thromboembolism (CAT) is a common complication associated with high morbidity and mortality. In accordance with major clinical trials comparing low-molecular-weight heparin (LMWH) with a vitamin K antagonist (VKA),...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Non-Vitamin K Oral Anticoagulants Associated Bleeding and Its Antidotes

Steiner T, Köhrmann , Schellinger PD, Tsivgoulis G

Oral anticoagulant-associated intracerebral hemorrhage (OAC-ICH) accounts for nearly 20% of all ICH. The number of patients with an indication for oral anticoagulant therapy (OAT) increases with increasing age. OAT became...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Oral Anticoagulants for Atrial Fibrillation Patients with Active Cancer

Kim DY, Lim HE

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer

Kim K, Lee YJ, Kim TH, Uhm JS, Pak HN, Lee MH, Joung B

BACKGROUND AND OBJECTIVES: There are limited data on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF) patients with cancer. We aimed to assess the efficacy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
2018 KHRS Expert Consensus Recommendation for Oral Anticoagulants Choice and Appropriate Doses: Specific Situation and High Risk Patients

Lee KH, Joung B, Lee SR, Hwang YM, Park J, Baek YS, Park YM, Park JK, Park HC, Park HW, Lee YS, Choi KJ

Oral anticoagulants (OAC) are necessary to prevent thromboembolism in patients with atrial fibrillation (AF). OACs used in Korea are composed of warfarin and non-vitamin K antagonist OAC. Risk stratification and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Adaptation of New Oral Anticoagulants for Warfarin Anticoagulated Patient with Traumatic Ongoing Hemorrhage

Ye JB, Sul YH, Lee JY, Go SJ, Choi JH

The traditional drug for anticoagulation in those with a high risk of thrombosis is a vitamin K antagonist, such as warfarin. On the other hand, this drug has several limitations...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risk Factors of Gastrointestinal Bleeding in Patients Receiving New Oral Anticoagulants

Lee JY

New oral anticoagulants (NOACs) are now widely used for the prevention and treatment of venous thrombosis, and for the prevention of stroke and systemic embolism in patients with atrial fibrillation....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism

Kim JH, Lim KM, Gwak HS

Anticoagulant drugs, like vitamin K antagonists and heparin, have been the mainstay for the treatment and prevention of venous thromboembolic disease for many years. Although effective if appropriately used, traditional...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Delayed bleeding after implant surgery in patients taking novel oral anticoagulants: a case report

Kim C, Dam C, Jeong J, Kwak EJ, Park W

The use of novel oral anticoagulants (NOACs) has increased in recent times in an effort to overcome the shortcomings of warfarin. They are being used primarily for the prevention of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Which of the Direct Oral Anticoagulants Is the Safest?: Based on Gastrointestinal Bleeding

Jung K, Park MI

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients

Joung B

Regulatory approvals of non-vitamin K antagonist oral anticoagulants (NOACs) have been based on large randomized phase III trials evaluating dabigatran, rivaroxaban, apixaban, or edoxaban relative to warfarin for atrial fibrillation...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr